<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107463">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728363</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00037820</org_study_id>
    <nct_id>NCT01728363</nct_id>
  </id_info>
  <brief_title>PK of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)</brief_title>
  <acronym>Staph</acronym>
  <official_title>Pharmacokinetics of Antistaphylococcal Antibiotics in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phillip Brian Smith</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple center, open-label, PK study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics of rifampin, ticarcillin-clavulanate, and clindamycin antibiotics in
      hospitalized infants with suspected systemic infection or receiving one of the study drugs
      per local standard of care.  Number of participants are 16-32 evaluable per each study drug
      of rifampin, ticarcillin-clavulanate, and clindamycin antibiotics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic concentrations in plasma will be measured at a central lab using a validated bioanalytical assay.  Plasma samples will be drawn according to specific schedules for each drug</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>to determine the Pharmacokinetics of rifampin, ticarcillin-clavulanate, and clindamycin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety review will be performed through monitoring of adverse events each day that the infant is on study</measure>
    <time_frame>7 days after last study dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>adverse events, serious adverse events, serious suspected adverse reactions, serious adverse reactions, suspected adverse reaction, adverse reactions will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Systemic Infection</condition>
  <arm_group>
    <arm_group_label>Ticarcillin-clavulanate antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort GA         PNA               Dose
&lt;30 weeks &lt;14 days:        75 mg/kg Q12 hrs x 6 doses
&lt;30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses
&lt;30 weeks &gt;45 days-90 days 75 mg/kg Q 6 hours x 6 doses
Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections.  It is a combination of two drugs &amp; both treat bacterial infections.  Ticarcillin is a penicillin-type antibiotic that stops bacterial growth &amp; clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin generic antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort GA         PNA         Dose
&lt;32 weeks &lt;14 days 10 mg/kg Q 24 hours x 4 doses
&lt;32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses
≥32 weeks &lt;14 days 15 mg/kg Q 24 hours x 4 doses
≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses
The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus &amp; staphylococcus epidermis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin Generic Antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort GA         PNA               Dose
&lt;30 weeks &lt;14 days        10 mg/kg Q 12 hours x 6 doses
&lt;30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses
&lt;30 weeks &gt;45 days-120 days 10 mg/kg Q 6 hours x 6 doses
The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic</intervention_name>
    <description>Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections.  Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.</description>
    <arm_group_label>Ticarcillin-clavulanate antibiotic</arm_group_label>
    <arm_group_label>Rifampin generic antibiotic</arm_group_label>
    <arm_group_label>Clindamycin Generic Antibiotic</arm_group_label>
    <other_name>Ticarcillin-clavulanate generic; Brand Timentin</other_name>
    <other_name>Rifampin generic; Brand Rifadin, Rimatane</other_name>
    <other_name>Clindamycin generic; Brand Cleocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sufficient intravascular access

          -  Suspected systemic infection or receiving 1 of the study drugs per standard of care

          -  informed consent from legal guardian

        Exclusion Criteria:

          -  history of allergic reaction to study drugs

          -  urine output &lt;0.5 mL/hr/kg over the prior 24 hours

          -  serum creatinine &gt;1.7 mg/dl

          -  Any condition in investigator judgment precludes participation because it could
             affect participant safety
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip B Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute and DUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Burchfield, MD</last_name>
      <phone>352-273-8985</phone>
      <email>burchdj@peds.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kamia Morris</last_name>
      <phone>352-294-5171</phone>
      <email>klmorris@peds.ufl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UFL Health and Baptist</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hudak, MD</last_name>
      <phone>904-244-3508</phone>
      <email>mark.hudak@jak.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Barnette</last_name>
      <phone>904-244-7760</phone>
      <email>kimberly.barnette@jax.ufl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Spearman, MD</last_name>
      <phone>404-727-5642</phone>
      <email>paulspearman@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brooke Hartwell, RN</last_name>
      <phone>404-727-5642</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Poindexter, MD</last_name>
      <phone>317-274-4768</phone>
      <email>bpoindex@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leslie D Wilson, RN</last_name>
      <phone>317-274-8255</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wesley Medical</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bloom T Bloom, MD</last_name>
      <phone>316-259-0810</phone>
      <email>barrybloom@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Sullivan, MD</last_name>
      <phone>502-852-3720</phone>
      <email>sully@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Kernen, RN</last_name>
      <phone>502-629-5044</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth McGowan, MD</last_name>
      <phone>617-240-4660</phone>
    </contact>
    <contact_backup>
      <last_name>Brittany Bressler, RN</last_name>
      <phone>617-636-1753</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kings County Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gratias Mundakel, MD</last_name>
      <phone>718-245-7048</phone>
      <email>gratias.mundakel@nychhc.org</email>
    </contact>
    <contact_backup>
      <last_name>Subhatra Limbu</last_name>
      <phone>917-375-4145</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Cotten, MD</last_name>
      <phone>919-681-4913</phone>
      <email>cotte010@mc.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Ross, RN</last_name>
      <phone>919-613-5158</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas Children's Hospital</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Shattuck, MD</last_name>
      <phone>409-772-2815</phone>
      <email>keshattu@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lori Simon, RN</last_name>
      <phone>409-747-9240</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>November 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University Medical Center</investigator_affiliation>
    <investigator_full_name>Phillip Brian Smith</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Staphylococcal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ticarcillin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin-2-phosphate</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Ticarcillin-clavulanic acid</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
